Androgen therapy in combination with granulocyte colony-stimulating factor and erythropoietin in a patient with refractory anemia
Katayama, Y.; Kojima, K.; Omoto, E.; Harada, M.
International Journal of Hematology 65(1): 89-92
1996
ISSN/ISBN: 0925-5710 PMID: 8990630 Document Number: 455960
Initial treatment with androgen (metenolone acetate) alone for 19 weeks had no effect in a 45-year-old Japanese female with refractory anemia (RA). The patient achieved trilineage hematologic recovery after addition of recombinant human granulocyte colony-stimulating factor (G-CSF) and recombinant human erythropoietin (Epo) to the androgen therapy. Anemia progressed after the cessation of metenolone acetate, but was effectively treated by the readministration of metenolone acetate. Thus, the androgen therapy in combination with hematopoietic growth factors such as G-CSF and/or Epo may be effective in patients with RA.